Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.6M
-
Number of holders
-
121
-
Total 13F shares, excl. options
-
32.8M
-
Shares change
-
+2.45M
-
Total reported value, excl. options
-
$112M
-
Value change
-
+$8.6M
-
Put/Call ratio
-
0
-
Number of buys
-
64
-
Number of sells
-
-48
-
Price
-
$3.43
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q2 2025
140 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q2 2025.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 121 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 32.8M shares
of 49.6M outstanding shares and own 66.05% of the company stock.
Largest 10 shareholders include ACORN CAPITAL ADVISORS, LLC (4.13M shares), BlackRock, Inc. (3.84M shares), VANGUARD GROUP INC (3.71M shares), ACADIAN ASSET MANAGEMENT LLC (2.01M shares), RENAISSANCE TECHNOLOGIES LLC (1.87M shares), AMERICAN CENTURY COMPANIES INC (1.34M shares), DIMENSIONAL FUND ADVISORS LP (1.15M shares), KENNEDY CAPITAL MANAGEMENT LLC (987K shares), GEODE CAPITAL MANAGEMENT, LLC (972K shares), and Connor, Clark & Lunn Investment Management Ltd. (900K shares).
This table shows the top 121 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.